Status:
COMPLETED
A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis
Lead Sponsor:
AstraZeneca
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
16+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate if treatment with AZD9668 for 28 days is effective in treating Cystic Fibrosis (CF) and if so how it compares to placebo (a substance which does not have an...
Eligibility Criteria
Inclusion
- Male or post-menopausal or surgically sterile female patients
- Have a clinical diagnosis of Cystic Fibrosis with lung function tests greater or equal to 40% of normal
- Have normal renal function
Exclusion
- Lung transplant patients
- Significant liver disease
- Any other non-CF-related lung disease that may interfere with study assessments
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00757848
Start Date
October 1 2008
End Date
August 1 2009
Last Update
August 20 2012
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Copenhagen, Denmark
2
Research Site
Hamburg, Germany
3
Research Site
Kiel, Germany
4
Research Site
Leipzig, Germany